Stay updated with breaking news from Marks Shearman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Editas Medicine (NASDAQ:EDIT – Get Rating) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday. A number of other brokerages also recently issued reports on EDIT. SVB Leerink lifted their price target on Editas Medicine from $6.00 to $7.00 and gave the stock a […]
Editas Medicine (NASDAQ:EDIT – Get Rating) released its earnings results on Friday. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.08, Briefing.com reports. The firm had revenue of $9.90 million for the quarter, compared to analyst estimates of $3.29 million. Editas Medicine had a negative […]
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) has been given a consensus recommendation of “Hold” by the sixteen brokerages that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and four have issued a buy recommendation on the company. The […]
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) shares shot up 8.4% during trading on Monday . The stock traded as high as $8.32 and last traded at $8.23. 443,238 shares were traded during trading, a decline of 75% from the average session volume of 1,793,685 shares. The stock had previously closed at $7.59. Wall Street […]
Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) have been given an average rating of “Hold” by the sixteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to […]